Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04181723 · ClinicalTrials.gov registry record · Phase 3

Study of Trofinetide for the Treatment of Girls and Women With Rett Syndrome (LAVENDER™)

A Phase 3 study, sponsored by ACADIA Pharmaceuticals.

Completed
Registry status
Phase 3
Development phase
187
Enrollment target

NCT04181723: Completed Phase 3 study, sponsored by ACADIA Pharmaceuticals.

NCT04181723 is a Phase 3 study that has completed, run by ACADIA Pharmaceuticals. The registered enrollment target is 187 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (76% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04181723, a Phase 3 study, has completed, sponsored by ACADIA Pharmaceuticals.

COMPLETED
Registry status
Phase 3
Development phase
187 participants
Enrollment target

Study Summary

To investigate the efficacy of treatment with oral trofinetide versus placebo in females with Rett syndrome

Primary Outcome

The RSBQ is a 45-item caregiver-completed rating scale that includes 45 items, 39 of them grouped into 8 subscales, whose ratings reflect the severity and frequency of symptoms. Items are rated as 0 (not true), 1 (somewhat or sometimes true), or 2 (very true). The 8 subscales are general mood, breathing problems, hand behavior, face movements, body rocking/expressionless face, night-time behaviors, fear/anxiety, and walking/standing. Scores for item 31 are reversed in the calculation of the tota

Interventions

  • OTHER Placebo
  • DRUG Trofinetide

Trial Details

FieldValue
Enrollment Target 187 participants
Start Date 2019-11-06
Est. Completion 2021-10-28
Phase Phase 3
ACADIA Pharmaceuticals

35 total trials

What the finished NCT04181723 record still lists

NCT04181723 is an interventional study that assigns participants to a tested intervention. The registered 187 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (76% lower).

The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.

NCT04181723 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT04181723 about?

NCT04181723 is a clinical study titled "Study of Trofinetide for the Treatment of Girls and Women With Rett Syndrome (LAVENDER™)". To investigate the efficacy of treatment with oral trofinetide versus placebo in females with Rett syndrome

What is the current status of trial NCT04181723?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 187 participants. The study started on 2019-11-06. Estimated completion is 2021-10-28.

What interventions are being tested in trial NCT04181723?

The interventions under investigation include: Placebo (OTHER), Trofinetide (DRUG).

Who is sponsoring clinical trial NCT04181723?

This trial is sponsored by ACADIA Pharmaceuticals, which has 35 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT04181723's enrollment target sits among peer trials

187 1410th of 2000 higher than 589 of 2,000 other Phase 3 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT06153251 · 187 participants · Phase 1

    A Study to Assess BMS-986453 in Participants With Relapsed and/or Refractory Multiple Myeloma

  • NCT06254898 · 187 participants · NA

    Use of Incentives for Stressful Medical Procedures

  • NCT07062237 · 187 participants · NA

    A Randomized Clinical Trial Comparing Embryo Euploidy Rates Following Ultrashort Versus Standard Abstinence

  • NCT07217574 · 187 participants

    Program in Oncology for Tribal Health Systems.

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT04181723, the US trial registry maintained by the National Library of Medicine. NCT04181723 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.